Meet FyoniBio at the European Multispecific Antibody Congress – Achieving successful clinical translation through refinement of design & engineering, expansion of target classes and novel biology, and demonstration of technologies in the clinic.

Why Attend?
The field of multi-specifics has accelerated, and substantial interest is owed to its flexibility, modularity, specificity and promise to be the ultimate set of modalities for precision oncology and beyond. As the field patiently waits for clinical trial readouts to feed into and optimise the overwhelming amount of preclinical candidates in the space, some say we are entering the next era and well into the 4th wave of drug discovery, beyond current targets and disease indications. Ongoing research efforts in academia and industry prepare us for the next wave of challenges that need to be overcome:

• Exploring novel biology, target and pathway selection for current and novel formats geared towards optimizing cancer targets and novel indications
• Innovative design and engineering challenges, developing assays that explore innovative format architecture in a rational way, away from long bouts of archaic trial and error and well into modelling and prediction
• Improving safety and efficacy profiles of current and emerging candidates
• Improving immune response modulation: to support the performance of multispecific drugs, exploring ways to tune/steer the immune response or induce synthetic immunity to mimic endogenous immune response, and study and prevent resistance mechanisms

Meet Ulrike Scheffler of the FyoniBio GmbH to discuss how FyoniBio’s expertise can contribute to the success of your clinical biopharmaceutical development programs!

Agenda
Speakers
Registration

Google Kalender